Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
25x-NBOMeLSD, psilocybin, psilocin +11 moreLSD, psilocybin, psilocin, mescaline, 2C-D, 2C-B, 2C-E, 2C-I, DOB, DOC, DOM, 25I-NBOMe, 25C-NBOMe, 25B-NBOMe show less
25D-NBOMe
2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine
25D-NBOMe is a synthetic psychedelic of the phenethylamine class. It is the N-(2-methoxybenzyl) derivative of 2C-D, dramatically more potent than its parent compound. It activates serotonin receptors in the brain,[1][2] producing the visual and cognitive shifts characteristic of classical psychedelics.
25D-NBOMe (2-(2,5-dimethoxy-4-methylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine) is a synthetic psychedelic of the phenethylamine class. It is the N-(2-methoxybenzyl) derivative of 2C-D, distinguished by dramatically higher potency. 25D-NBOMe is a full agonist at the 5-HT₂A receptor, producing its effects by activating Gq/11-coupled serotonin signaling in cortical neurons.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
25x-NBOMeLSD, psilocybin, psilocin +11 moreLSD, psilocybin, psilocin, mescaline, 2C-D, 2C-B, 2C-E, 2C-I, DOB, DOC, DOM, 25I-NBOMe, 25C-NBOMe, 25B-NBOMe show less
The NBOMe series originated in academic receptor research around 2000, developed as a pharmacological tool.citation needed These compounds reached online markets around 2010 on blotter paper visually identical to LSD — a persistent source of misidentification; 25D-NBOMe was first confirmed in seized blotter in 2013.[3] It is not specifically scheduled by name in most countries, falling instead under structural analog provisions and blanket bans.
Subjective effects include brightened colors, visual patterning, introspective thought, muscle tension, and a persistent cardiovascular awareness — elevated heart rate and peripheral tension. The experience is closest to LSD in perceptual character, but the body competes with the mind for attention throughout. Nausea, vasoconstriction, and anxious body-focus are common unwanted effects, and at higher doses somatic discomfort can overshadow the psychedelic experience.
Physical dependence is not documented, but animal studies show 25D-NBOMe activates dopamine reward circuits,[4] and tolerance builds rapidly after each use.[5] It disrupts a heart channel that controls normal rhythm,[6] and the broader NBOMe class is linked to seizures, dangerous overheating, and organ failure. Human research is almost entirely absent — the current understanding rests on one animal study, class-level case reports, and user accounts.
History[edit]
Discovery
The parent compound 2C-D was described by Alexander Shulgin in PiHKAL (1991).citation needed Ralf Heim first synthesized N-(2-methoxybenzyl) variants around 2000 as pharmacological research tools.citation needed Michael Braden's 2007 doctoral work demonstrated that this modification turned moderate-potency 2C compounds into some of the most potent serotonergic agonists then known.[7]
Emergence in drug supply
NBOMe compounds appeared on online research chemical markets around 2010, distributed on blotter paper visually identical to LSD.[8][9] Multiple variants circulated under the class-level names "N-bomb," "Smiles," and "Solaris." 25D-NBOMe was first analytically confirmed in seized blotter in 2013.[3]
Regulatory response
The United States placed 25I-, 25B-, and 25C-NBOMe into Schedule I in November 2015.[10] 25D-NBOMe was not named but remains subject to the Federal Analogue Act. The United Kingdom classified NBOMe compounds as Class A following a Temporary Class Drug Order in June 2013.[11]
The "25" prefix denotes an N-benzyl substitution on a 2C compound; "D" specifies the 4-methyl substituent inherited from 2C-D; "NBOMe" abbreviates N-(2-methoxybenzyl). No street names specific to 25D-NBOMe are documented — it circulates under class-level labels shared with more common variants. Among research chemical users, 25D-NBOMe is one of the more obscure members of the series, overshadowed by the wider availability of 25I-NBOMe.
Chemistry[edit]
Structural class
25D-NBOMe belongs to the NBOMe subclass of substituted phenethylamines. Its parent compound is 2C-D, first described by Alexander Shulgin.citation needed Attaching a 2-methoxybenzyl group to the amine nitrogen of 2C-D dramatically increases binding strength at serotonin receptors,[8][12] converting a moderate-potency psychedelic into one active at microgram doses.[1]
Molecular properties
The molecular formula is C₁₉H₂₅NO₃ (molecular weight 315.4 g/mol). Three methoxy groups and one methyl group decorate the aromatic rings, giving the compound moderate lipophilicity. The hydrochloride salt is the form typically identified in seized blotter samples.[3]
Pharmacology[edit]
Mechanism of action
25D-NBOMe activates serotonin receptors as a full agonist — the same target responsible for the effects of LSD and psilocybin.[1] The N-(2-methoxybenzyl) modification dramatically increases binding strength, making it active at microgram-level doses.[8][1] Unlike classical psychedelics, it also activates dopamine reward circuits — in the only compound-specific study, rats self-administered it, a marker of reinforcing potential.[4]
Cardiotoxicity
25D-NBOMe disrupts a potassium channel in the heart responsible for maintaining normal rhythm — the same channel blocked by several drugs known to cause fatal arrhythmias.[6] In rats, this produced measurable electrical delays in the heart's cycle. No human cardiac data exist. safety citation needed
Pharmacokinetics
No human pharmacokinetic studies exist for 25D-NBOMe. Oral ingestion is inactive — the compound breaks down before reaching the bloodstream,[8] so sublingual or buccal placement is standard. One user report at 1,600 µg documented onset around 10 minutes and total duration around 8 hours;[13] class-level data suggest 4–8 hours total.[9] The liver processes it primarily by stripping methoxy groups,[14] with metabolites excreted in urine.[15]
Neuroscience[edit]
Where it acts
25D-NBOMe's main target is a serotonin receptor densely concentrated in the prefrontal cortex and association areas.[16][8] Activating these receptors increases excitatory brain signaling, disrupts sensory filtering, and pushes the brain toward greater global connectivity.[16] The result is the characteristic psychedelic signature: perceptual fluidity, loosened network organization, and dissolution of the mental structures that normally constrain thought.
The dopamine activity documented in animal research[4] adds a reward-circuit dimension absent from classical psychedelics. This may shape the experience and explain the compound's reinforcing properties in ways that serotonin-only models cannot capture.
Theoretical frameworks
Current theory proposes that psychedelics flatten the brain's belief hierarchy, allowing raw sensory input to override learned expectations.citation needed Whether 25D-NBOMe also drives structural changes in brain cells — new connections and synapse growth, as demonstrated for psilocybin and LSD — has not been studied.citation needed
Key unknowns include whether 25D-NBOMe produces lasting structural brain changes comparable to psilocybin or LSD, and whether the dopamine reward-circuit activation documented in animals leads to compulsive redosing in humans. The heart channel disruption found in cell studies[6] has not been tested at psychedelic doses in people. The threshold for nerve cell damage found in cell lines[17] also remains unknown in living organisms.
Subjective Effects[edit]
The 25D-NBOMe experience is defined by tension between psychedelic openness and somatic vigilance. Cardiovascular awareness — elevated heart rate, peripheral tension, vasoconstriction — runs as a constant undercurrent. At lower doses, introspective calm dominates; at higher doses, anxious physical awareness can consume most of the available attention.
The perceptual character is closest to LSD — vivid color shifts, pattern recognition, conceptual loosening — but with a heavier physical footprint. Where psilocybin and LSD tend to carry relatively clean body profiles, 25D-NBOMe's somatic weight is one of its most defining features.
The NBOMe series emerged from academic receptor research at the Free University of Berlin around 2000, with further development in the Nichols laboratory at Purdue University. 25D-NBOMe entered online research chemical markets around 2010 and was first analytically confirmed in seized blotter papers in 2013.[3] It remains unscheduled by name in most jurisdictions, falling instead under structural analog provisions and blanket bans.
Subjective effects include perceptual enhancement, color intensification, introspective thought, and muscle tension. The experience is defined by a heavy sympathomimetic body load — tachycardia and cardiovascular awareness competing with the psychedelic effects for the user's attention, a duality more pronounced than with classical psychedelics. Anxious somatic preoccupation, nausea, and vasoconstriction are characteristic unsought effects.
No physical dependence has been documented, but rodent studies demonstrate reinforcing properties through dopaminergic reward-circuit activation.[4] Rapid tolerance develops through downregulation,[5] while substance-specific cardiac toxicity — hERG channel inhibition and QT prolongation[6] — compounds the class-wide risk of seizures, hyperthermia, and organ failure. No controlled human studies exist; the current understanding rests on one preclinical study, class-level case reports, and user reports.
History[edit]
Discovery
The NBOMe series of phenethylamines originated in academic research at the Free University of Berlin, where Ralf Heim first synthesized N-(2-methoxybenzyl)-substituted phenethylamines as pharmacological tools around 2000.citation needed The parent compound — 2C-D — had been described earlier by Alexander Shulgin in PiHKAL (1991), where he noted its mild psychedelic effects and nicknamed it "pharmacological tofu" for its utility as a baseline phenethylamine.citation needed Michael Braden's 2007 doctoral work in the Nichols laboratory at Purdue University demonstrated that the N-(2-methoxybenzyl) modification converted moderate-potency 2C compounds into some of the most potent serotonergic agonists then known.[7]
Emergence in drug supply
NBOMe compounds appeared on online research chemical markets beginning around 2010, distributed primarily on blotter paper visually indistinguishable from LSD.[8][9] Multiple variants circulated under class-level street names including "N-bomb," "Smiles," and "Solaris." 25D-NBOMe was first analytically confirmed from seized blotter papers by Zuba and Sekuła in 2013.[3]
Regulatory response
The proliferation of NBOMe compounds prompted rapid scheduling actions. The United States placed 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe into Schedule I in November 2015;[10] 25D-NBOMe was not named but remains subject to the Federal Analogue Act. The United Kingdom classified NBOMe compounds as Class A following a Temporary Class Drug Order in June 2013.[11]
The "25" prefix denotes an N-benzyl substitution on a 2C compound; "D" specifies the 4-methyl substituent inherited from 2C-D; and "NBOMe" abbreviates N-(2-methoxybenzyl). No street names specific to 25D-NBOMe are documented — it circulates under the class-level labels shared with more common NBOMe variants. Among research chemical users, 25D-NBOMe is considered one of the more obscure members of the series, overshadowed by the notoriety and wider availability of 25I-NBOMe.
Chemistry[edit]
Structural class
25D-NBOMe belongs to the NBOMe (N-(2-methoxybenzyl)) subclass of substituted phenethylamines. Its parent compound is 2C-D (2,5-dimethoxy-4-methylphenethylamine), a phenethylamine psychedelic first described by Alexander Shulgin.citation needed The structural transformation from 2C-D to 25D-NBOMe involves appending a 2-methoxybenzyl group to the primary amine nitrogen — a modification that dramatically increases binding strength at the 5-HT₂A receptor by enabling additional contacts with extracellular loop regions.[8][12]
Molecular properties
| Molecular formula | C₁₉H₂₅NO₃ |
| Molecular weight | 315.4 g/mol |
The molecule comprises a 2,5-dimethoxy-4-methylphenethylamine core — the 2C-D scaffold — with a 2-methoxybenzyl group bonded to the amine nitrogen. Three methoxy groups and one methyl group decorate the aromatic rings, giving the compound moderate lipophilicity. The hydrochloride salt is the form typically encountered in analytical seizure reports and on blotter preparations.[3]
Stereochemistry
25D-NBOMe lacks a chirality center. Nitrogen inversion renders the amine configurationally labile, so the compound exists as a single achiral entity. Stereoisomer considerations do not apply.
Pharmacology[edit]
Mechanism of action
25D-NBOMe activates the serotonin 5-HT₂A receptor as a full agonist — the same molecular target responsible for the effects of classical psychedelics like LSD and psilocybin.[1] The N-(2-methoxybenzyl) group attached to the 2C-D scaffold dramatically increases binding strength at this receptor, producing psychedelic effects at microgram-level doses.[8][1] The compound also activates 5-HT₂C receptors with potency comparable to LSD,[1] while showing very low activity at 5-HT₁A.[1][9]
Unlike classical psychedelics, 25D-NBOMe produces measurable changes in the brain's dopamine reward circuitry. In the only study conducted specifically on this compound, Lee and colleagues demonstrated that 25D-NBOMe increased dopamine release in the nucleus accumbens of rats and produced self-administration and conditioned place preference — behavioral markers of reinforcing potential.[4] These dopaminergic effects distinguish NBOMe compounds from classical psychedelics, which generally lack reward-circuit activation.
NBOMe compounds as a class also show affinity at adrenergic, dopamine, and histamine receptors,[13] though specific binding data at these secondary targets have not been published for 25D-NBOMe. Interactions with monoamine transporters occur only at concentrations far above psychedelic doses, confirming a hallucinogenic rather than stimulant mechanism.[1]
Cardiotoxicity
Yoon and colleagues (2019) demonstrated that 25D-NBOMe inhibits hERG potassium channels — the molecular mechanism behind drug-induced heart rhythm abnormalities.[6] In rats, intravenous administration at 2.0 mg/kg produced measurable QT interval prolongation. At high concentrations, the compound reduced cardiac cell viability in laboratory assays.[6] safety citation needed No human heart data exist for 25D-NBOMe.
Pharmacokinetics
No human pharmacokinetic studies exist for 25D-NBOMe. All parameters are inferred from structurally similar NBOMe compounds and limited user reports.
Sublingual or buccal administration is the standard route — oral ingestion is inactive or very weakly active due to breakdown in the gut and extensive first-pass liver metabolism.[8] Onset occurs 20–40 minutes after sublingual placement. A single indexed user report of buccal administration at 1,600 µg documented onset at approximately 10 minutes, peak effects at approximately 50 minutes, and a total duration of approximately 8 hours.[14] Class-level data suggest peak effects at 1–2 hours and total duration of 4–8 hours.[9]
Based on studies of related NBOMe compounds, metabolism proceeds primarily through removal of methoxy groups from the aromatic rings, with secondary hydroxylation pathways.[15] Metabolites undergo further processing before urinary excretion.[16] Plasma half-life, bioavailability, and protein binding have not been determined for 25D-NBOMe in any species.
Neuroscience[edit]
Where it acts
25D-NBOMe's primary target — the 5-HT₂A receptor — is densely expressed on pyramidal neurons in the prefrontal cortex and association cortices.[17][8] Activation of these receptors increases glutamate release, disrupts thalamic sensory filtering, and shifts the brain toward greater global connectivity at the expense of organized network function.[17] This produces the characteristic psychedelic signature: dissolution of the default mode network, increased neural signal complexity, and the perceptual fluidity that users experience as visual and cognitive distortion.
The dopaminergic activity documented by Lee and colleagues — increased dopamine release in the nucleus accumbens[4] — adds a reward-circuit dimension absent from classical psychedelics. This dual serotonergic-dopaminergic action may explain the compound's reinforcing properties and could shape the subjective experience in ways not captured by models built on purely serotonergic compounds.
Theoretical frameworks
The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that psychedelics flatten the brain's belief hierarchy, allowing bottom-up sensory signals to override top-down expectations.citation needed As a potent 5-HT₂A agonist, 25D-NBOMe would be expected to produce this effect — resulting in the perceptual novelty and conceptual flexibility typical of the psychedelic state. Whether the compound also drives structural neuroplasticity (new dendritic growth and synapse formation), as demonstrated for other serotonergic psychedelics, has not been tested.citation needed
Key unknowns include whether 25D-NBOMe produces lasting structural changes in neurons comparable to psilocybin or LSD, and whether the dopaminergic reward-circuit activation translates to compulsive redosing patterns in humans. The cardiac risk question is also unresolved: hERG channel inhibition documented in vitro[6] has not been tested at psychedelic doses in humans.
Subjective Effects[edit]
The 25D-NBOMe experience is one in which the body competes with the mind for attention. Cardiovascular awareness — a pounding heart, peripheral tension, vasoconstriction — runs as a constant undercurrent beneath the perceptual effects, creating a push-pull between psychedelic openness and somatic vigilance. At lower doses, introspective tranquility tends to dominate; at higher doses, anxious body-focus can overshadow the perceptual and cognitive dimensions. Set and setting exert an unusually strong influence on which side of this balance prevails.
Users position the experience closest to LSD in perceptual character — vivid color shifts, pattern recognition, conceptual loosening — but with a heavier physical footprint and a narrower window between desired effects and discomfort. The somatic weight distinguishes it sharply from the relatively clean body profiles of psilocybin or LSD.
Effect Grid
A clear psychedelic state with visual breathing, color enhancement, and geometric patterning across surfaces. Visual drifting and tracers are present. Music enhancement and immersion enhancement become noticeable. Introspective thought deepens with manageable cognitive alteration — thought acceleration and conceptual thinking emerge without overwhelming confusion.
The sympathomimetic body load becomes a defining feature: elevated heart rate, muscle tension, pupil dilation, and vasoconstriction are prominent. Appetite suppression is reliable. Temperature dysregulation — alternating warmth and chills — may occur. Wakefulness and stimulation are sustained throughout.
Most users report this range as the intended psychedelic experience. Duration spans 4–6 hours with residual stimulation preventing sleep for 6–8 hours post-administration.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Visual drifting · Visual morphing · After-images · Brightness alteration · Environmental patterning · Light sensitivity · Music enhancement · Peripheral vision distortion · Symmetrical texture repetition · Visual diffraction · Visual melting · Depth perception distortion · Perspective distortion · Spatial disorientation · Touch enhancement · Visual haze / noise · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Sound sensitivity · Vestibular distortion · Visual acuity enhancement · Visual processing acceleration · Auditory enhancement · Synesthesia · Tinnitus · Visual magnification · Flashbacks · Object transformations · Visual recursion · External hallucinations · Internal hallucinations · Object activation · Auditory hallucinations · Persisting hallucinations
Brightness alteration · Environmental patterning · Light sensitivity · Music enhancement · Peripheral vision distortion · Symmetrical texture repetition · Visual diffraction · Visual melting · Depth perception distortion · Perspective distortion · Spatial disorientation · Touch enhancement · Visual haze / noise · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Sound sensitivity · Vestibular distortion · Visual acuity enhancement · Visual processing acceleration · Auditory enhancement · Synesthesia · Tinnitus · Visual magnification · Flashbacks · Object transformations · Visual recursion · External hallucinations · Internal hallucinations · Object activation · Auditory hallucinations · Persisting hallucinations
Dry mouth · Excessive sweating · Insomnia · Muscle tension · Nausea · Physical fatigue · Restlessness · Appetite suppression · Headache · Heart rate perception changes · Spontaneous body sensations · Tingling / electric sensations · Vibrations / buzzing · Bodily pressures · Body schema distortion · Dizziness · Laughter fits · Tactile euphoria · Trembling · Bruxism · Involuntary body movements · Nystagmus (eye wobbles) · Respiratory stimulation · Vomiting · Bodily dissociation · Tactile hallucination
Nausea · Physical fatigue · Restlessness · Appetite suppression · Headache · Heart rate perception changes · Spontaneous body sensations · Tingling / electric sensations · Vibrations / buzzing · Bodily pressures · Body schema distortion · Dizziness · Laughter fits · Tactile euphoria · Trembling · Bruxism · Involuntary body movements · Nystagmus (eye wobbles) · Respiratory stimulation · Vomiting · Bodily dissociation · Tactile hallucination
Analysis suppression · Cognitive dysphoria · Cognitive euphoria · Cognitive impairment · Conceptual thinking · Confusion · Immersion enhancement · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought acceleration · Thought connectivity · Thought disorganization · Cognitive fatigue · Cognitive flexibility · Creativity enhancement · Focus suppression · Increased nature relatedness · Information processing suppression · Memory fragmentation · Thought loops · Analysis enhancement · Humor enhancement · Memory replays · Synchronicity · Delirium · Delusions
Cognitive impairment · Conceptual thinking · Confusion · Immersion enhancement · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought acceleration · Thought connectivity · Thought disorganization · Cognitive fatigue · Cognitive flexibility · Creativity enhancement · Focus suppression · Increased nature relatedness · Information processing suppression · Memory fragmentation · Thought loops · Analysis enhancement · Humor enhancement · Memory replays · Synchronicity · Delusions
Emotional lability · Simultaneous emotions · Dysphoria · Irritability · Catharsis
Catharsis
Depersonalization · Disinhibition · Sociability suppression · Social disconnection · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration
Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration
Timeline
Bitter, numbing taste on sublingual contact. Initial alertness and mild stimulation emerge. Faint perceptual brightening may be noticed.
Rapid intensification of visual and somatic effects. Color enhancement, surface texturing, and tachycardia become noticeable. Pupil dilation develops.
Full psychedelic state — vivid color enhancement, geometric patterning, visual breathing, and introspective thought. Prominent sympathomimetic body load: elevated heart rate, muscle tension, vasoconstriction. Emotional and cognitive effects reach maximum intensity.
Gradual diminution of visual effects. Body stimulation and cardiovascular awareness persist longer than perceptual changes. Thought patterns begin normalizing.
Residual stimulation and mild wakefulness. Reflective mood with possible residual visual enhancement. Insomnia is common.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- LSD · psilo · psilocin
Toxicity
No lethal dose has been established for 25D-NBOMe, and the margin between a psychedelic dose and a dangerous one is unknown. safety citation needed
Cardiovascular toxicity
25D-NBOMe disrupts a potassium channel in the heart responsible for maintaining normal rhythm.[6] In rats, this produced measurable electrical delays — a precursor to a potentially fatal irregular heartbeat called torsades de pointes. These are animal findings; the dose at which cardiac effects emerge in humans is unknown.
Class-level toxicity
The broader NBOMe class carries a documented pattern of severe toxicity[9][18]:
- Rapid heart rate, high blood pressure, and dangerously elevated body temperature
- Seizures and extreme agitation
- Muscle breakdown with secondary kidney injury
- Blood clotting dysfunction and metabolic crisis
- Multiple organ failure
Multiple deaths have been attributed to 25I-NBOMe,[19] 25B-NBOMe,[20] and 25C-NBOMe.[21] 25D-NBOMe was found in a mixed-NBOMe fatality case but has not been attributed as the sole cause.[22]
Neurotoxicity
NBOMe compounds damage nerve cells at higher concentrations than their parent 2C compounds.[17] Chronic use in rats produced markers of genetic damage and brain inflammation.[5] The dose at which this becomes relevant in humans is unknown.
Psychological risks
No controlled human studies exist. Class-level risks for NBOMe compounds include[8][9]:
- Acute distress: anxiety, paranoia, and agitation at recreational doses; extreme agitation and loss of control at high doses
- Psychotic episodes: Paranoia, hallucinations, and delusional thinking reported for 25I- and 25C-NBOMe; no 25D-NBOMe-specific cases exist
- HPPD: Persistent visual changes after the drug has cleared — documented in the class, not specifically attributed to 25D-NBOMe
The single available user report (1,600 µg buccal) described the mental space as tranquil but noted significant distress from cardiovascular effects.[13]
Tolerance & dependence
Tolerance builds rapidly through serotonin downregulation after each use.[5] Cross-tolerance is expected with LSD, psilocybin, 2C-series, and DOx compounds — all acting through the same receptor.
Dependence liability is uncertain. Rodent studies confirmed reinforcing properties — rats self-administered the compound, with dopamine changes in reward centers as the mechanism.[4] Whether this translates to human dependence is unknown. safety citation needed No physical withdrawal has been documented for any NBOMe compound.
Drug Interactions
All assessments below are based on pharmacological inference. inferred
Tramadol is dangerous. It raises serotonin levels, creating risk of serotonin syndrome — a potentially life-threatening overheating and seizure response. Its seizure-lowering properties also add to the seizure risk carried by NBOMe compounds at high doses.[16]
Cocaine is dangerous. Both constrict blood vessels and carry independent cardiac toxicity — 25D-NBOMe through heart channel disruption,[6] cocaine through epinephrine-driven cardiac stress.[16]
MDMA raises serotonin flooding risk — adding more serotonin on top of already-activated serotonin receptors increases the chance of a dangerous overheating response. safety citation needed
Lithium combined with serotonergic psychedelics carries documented seizure risk in the class literature. safety citation needed
Cannabis interaction is uncharacterized. No specific data exist.
Contraindications
9 knownNo substance-specific data have been published. The following derive from pharmacological profile and class-level safety data.
Absolute contraindications:
- Pre-existing heart rhythm abnormalities or prolonged QT interval: Heart channel disruption[6] creates direct risk of fatal arrhythmia
- QT-prolonging medications: Certain heart medications, antipsychotics, and antibiotics — additive risk safety citation needed
- Seizure disorders: NBOMe compounds lower seizure threshold at high doses[8]
- Serotonergic medications: MAOIs, SSRIs, SNRIs, tramadol — serotonin syndrome risk
Relative contraindications:
- Cardiovascular disease: Sympathomimetic effects stress the heart and blood vessels
- Electrolyte imbalances: Low potassium and magnesium increase susceptibility to heart rhythm problems
- Liver impairment: Predicted reliance on liver metabolism suggests impaired clearance inferred
- Psychiatric conditions: History of psychotic disorders — class-level risk of triggering psychotic episodes
Harm Reduction[edit]
Forms & Identification
The main identification challenge is distinguishing 25D-NBOMe from LSD. Both circulate on visually identical blotter paper. NBOMe compounds produce a pronounced bitter, numbing taste on sublingual contact — LSD is tasteless. This taste difference is a useful initial signal but unreliable as a sole identification method.
Reagent testing can differentiate NBOMe compounds from LSD but cannot identify the specific NBOMe variant. Laboratory analysis — such as mass spectrometry through drug checking services — is the only way to confirm the specific compound.
Guidelines
- Test all material with reagent kits before use — at minimum, verify the substance is not being sold as LSD
- Start with the lowest reported active dose and wait at least 90 minutes before considering any adjustment — the dose-response curve is poorly characterized
- Choose a calm, comfortable, and familiar environment with easy access to outdoors
- Have a sober, trusted companion present throughout the experience
- Stay hydrated but avoid excessive water intake
- Avoid physical exertion — the cardiovascular load is already significant
- Keep emergency contact information accessible
Set & Setting
The pronounced body load and narrow margin between comfortable and distressing effects make set and setting unusually important. A calm, familiar environment with fresh air and comfortable seating reduces the risk of anxiety spiraling from cardiovascular awareness. An experienced, sober companion is strongly recommended given the compound's limited characterization and unpredictable dose-response.
Aftercare & integration. The heavy body load can leave residual tension and fatigue into the following day. Gentle stretching, adequate hydration, and rest support physical recovery. Light, easily digestible food is preferable for the first meal afterward.
The experience may surface unexpected emotional material or leave lingering unease — particularly if significant anxiety occurred during the session. Journaling within 24–48 hours helps preserve insights and process difficult moments. Persistent distressing thoughts or perceptual changes beyond a few days warrant consultation with a mental health professional familiar with psychedelic experiences.
Recovery & Support
Classical psychedelics rarely produce compulsive use, but 25D-NBOMe's demonstrated dopaminergic reward-circuit activity introduces uncertainty. Urges to use more frequently, difficulty maintaining intended breaks, or escalating doses are warning signs.
Support resources include harm reduction organizations, psychedelic peer support networks, and addiction counseling services. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Uncomfortable heart rate and body tension are common at active doses. Seek immediate medical help if any of the following occur: chest pain, seizure or convulsions, loss of consciousness, rigid or extremely elevated body temperature (hot to touch through clothing), severe confusion or complete disconnection from reality, or signs of self-harm.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Place the person on their side (recovery position) if unconscious or seizing — do not restrain them
- 3. Move to a cool, quiet environment if possible
- 4. Do not induce vomiting
- 5. Monitor breathing and temperature while waiting for help
What to tell the dispatcher:
Provide the substance name (25D-NBOMe or "an NBOMe compound"), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for NBOMe overdose. Treatment is supportive.
Legal Status[edit]
25D-NBOMe has not been specifically named in most drug laws. In most countries it falls under structural analog provisions, blanket bans, or structural catch-all definitions rather than explicit scheduling.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled; Federal Analogue Act applies | 25I-, 25B-, and 25C-NBOMe placed in Schedule I on November 13, 2015.[10] 25D-NBOMe not named but covered under 21 U.S.C. § 813 if intended for human consumption. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled via N-benzylphenethylamine catch-all clause. Temporary Class Drug Order issued June 10, 2013,[11] subsequently made permanent. |
| European Union | Not specifically scheduled at EU level | 25I-NBOMe subjected to EU-wide control under Council Decision 2015/1875.[23] 25D-NBOMe not included. Member state laws vary. |
| Sweden | Controlled substance | Scheduled from August 1, 2013.[24] |
| Canada | Schedule I (CDSA) | Covered under phenethylamine blanket-ban language in the Controlled Drugs and Substances Act. |
| Australia | State-level controls | Phenethylamine blanket-ban language covers NBOMe compounds in Queensland and New South Wales from April 2014 onward.[24] |
| Brazil | Controlled | NBOMe class controlled from approximately February 2014.[24] |
Analog act considerations
In the United States, 25D-NBOMe's structural similarity to Schedule I NBOMe compounds makes it subject to the Federal Analogue Act when intended for human consumption.[1] Prosecution requires demonstrating both structural and pharmacological similarity — a standard this compound meets by published receptor data.
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current laws before acting on this information.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- LSD · psilo · psilocin
Toxicity
No lethal dose has been established for 25D-NBOMe in any species, and no therapeutic index can be calculated. The margin between a psychedelic dose and a potentially dangerous dose is unknown. safety citation needed
Cardiovascular toxicity
The most significant substance-specific finding is that 25D-NBOMe inhibits hERG potassium channels — the molecular target responsible for drug-induced heart rhythm abnormalities.[6] In rats, intravenous administration at 2.0 mg/kg produced measurable QT interval prolongation, a precursor to a potentially fatal heart rhythm called torsades de pointes.[6] These are animal and cell-line findings; the dose at which cardiac effects emerge in humans is unknown.
Class-level toxicity
The broader NBOMe class carries a documented pattern of severe toxicity[9][13]:
- Rapid heart rate, high blood pressure, and dangerously elevated body temperature
- Seizures and extreme agitation
- Muscle breakdown with secondary kidney injury
- Blood clotting dysfunction and metabolic crisis
- Multiple organ failure
Multiple deaths have been attributed to 25I-NBOMe,[19] 25B-NBOMe,[20] and 25C-NBOMe.[21] No fatality has been attributed solely to 25D-NBOMe, though it was found as a component of mixed-NBOMe blotter in a fatality case.[22]
Neurotoxicity
NBOMe compounds produce higher toxicity to nerve cells than their parent 2C compounds, with damage occurring through energy depletion and loss of cellular protective mechanisms.[18] Chronic administration in rats produced markers of genetic damage and brain inflammation.[5] The dose at which these effects become relevant in humans is unknown.
Psychological risks
No controlled studies of the psychological effects of 25D-NBOMe have been conducted. Class-level risks for NBOMe compounds include[8][9]:
- Acute psychological distress: anxiety, paranoia, and agitation at recreational doses; at high doses, extreme agitation and uncontrollable behavior
- Psychotic episodes: delusions and disorganized behavior reported for 25I-NBOMe and 25C-NBOMe; no 25D-NBOMe-specific case reports exist
- HPPD: No cases of Hallucinogen Persisting Perception Disorder have been attributed specifically to 25D-NBOMe, though HPPD is documented for the class
The single available user report (1,600 µg buccal) described the mental space as tranquil but noted significant physical distress from cardiovascular effects.[14]
Tolerance & dependence
Tolerance develops rapidly through 5-HT₂A downregulation following exposure.[5] Cross-tolerance is expected with LSD, psilocybin, 2C-series compounds, and DOx compounds — all of which act through the same receptor. The rate and duration of tolerance specific to 25D-NBOMe have not been measured.
Dependence liability is uncertain. Classical psychedelics generally carry low dependence risk, but 25D-NBOMe's dopaminergic reward-circuit activation sets it apart. Rodent studies confirmed reinforcing properties — rats self-administered the compound and showed conditioned place preference, with dopamine changes in the nucleus accumbens as the underlying mechanism.[4] Whether this translates to human dependence is unknown. safety citation needed No physical withdrawal has been documented for any NBOMe compound.
Drug Interactions
The interaction profile of 25D-NBOMe has not been systematically studied. All assessments below are based on pharmacological mechanisms and class-level inference. inferred
Tramadol is classified as dangerous. Tramadol's serotonergic activity creates serotonin syndrome risk, and its seizure-lowering properties combine additively with the seizure risk already carried by NBOMe compounds at high doses.[17]
Cocaine is classified as dangerous. Both compounds constrict blood vessels, and both carry independent heart toxicity risk — 25D-NBOMe through hERG channel inhibition,[6] cocaine through sodium channel blockade and catecholamine-driven cardiac stress.[17]
MDMA presents serotonin syndrome risk through its mechanism of flooding the synapse with serotonin. safety citation needed
Lithium combined with serotonergic psychedelics carries documented seizure risk in the class literature and should be considered potentially dangerous. safety citation needed
Cannabis interaction is uncharacterized. No specific data exist for this combination.
Contraindications
9 knownNo substance-specific contraindication data have been published. The following are derived from pharmacological profile and class-level safety data.
Absolute contraindications:
- Pre-existing heart rhythm abnormalities or prolonged QT interval: hERG channel inhibition[6] creates direct risk of fatal arrhythmia
- QT-prolonging medications: Certain heart medications, antipsychotics, and antibiotics — additive QT prolongation risk safety citation needed
- Seizure disorders: NBOMe compounds lower seizure threshold at high doses[8]
- Serotonergic medications: MAOIs, SSRIs, SNRIs, tramadol — serotonin syndrome risk
Relative contraindications:
- Cardiovascular disease: Sympathomimetic effects stress the heart and blood vessels
- Electrolyte imbalances: Low potassium and magnesium increase susceptibility to heart rhythm problems
- Liver impairment: Predicted reliance on liver metabolism suggests impaired clearance inferred
- Psychiatric conditions: History of psychotic disorders — class-level risk of triggering psychotic episodes
Harm Reduction[edit]
Forms & Identification
The primary identification challenge with 25D-NBOMe is distinguishing it from LSD. Both circulate on visually identical blotter paper, but NBOMe compounds produce a pronounced bitter, numbing taste on sublingual contact — LSD is tasteless. This taste test is a useful initial signal but is unreliable as a sole identification method.
Reagent testing can differentiate NBOMe compounds from LSD but cannot distinguish between individual NBOMe variants. Laboratory-grade analysis (such as mass spectrometry through drug checking services) is the only way to confirm the specific compound present.
Guidelines
- Test all material with reagent kits before use — at minimum, verify the substance is not being sold as LSD
- Start with the lowest reported active dose and wait at least 90 minutes before considering any adjustment — the dose-response curve is poorly characterized
- Choose a calm, comfortable, and familiar environment with easy access to outdoors
- Have a sober, trusted companion present throughout the experience
- Stay hydrated but avoid excessive water intake
- Avoid physical exertion — the cardiovascular load is already significant
- Keep emergency contact information accessible
Set & Setting
The pronounced body load and narrow margin between comfortable and distressing effects make set and setting unusually important for 25D-NBOMe. A calm, familiar environment with access to fresh air and comfortable seating reduces the likelihood of anxiety spiraling from cardiovascular awareness. An experienced, sober companion is strongly recommended given the compound's limited characterization and unpredictable dose-response.
Aftercare & integration. The heavy body load of 25D-NBOMe can leave residual physical tension and fatigue lasting into the following day. Gentle stretching, adequate hydration, and rest support physical recovery. Light, easily digestible food is preferable for the first meal after the experience.
Psychologically, the experience may surface unexpected emotional material or leave a lingering sense of unease — particularly if significant anxiety occurred during the session. Journaling within 24–48 hours helps preserve insights and process difficult moments. If distressing thoughts or perceptual changes persist beyond a few days, consultation with a mental health professional familiar with psychedelic experiences is appropriate.
Recovery & Support
While classical psychedelics rarely produce compulsive use patterns, 25D-NBOMe's demonstrated dopaminergic reward-circuit activity introduces uncertainty about its dependence potential. Anyone experiencing urges to use more frequently, difficulty maintaining intended breaks between uses, or escalating doses should consider this a warning sign.
Support resources include harm reduction organizations, psychedelic peer support networks, and addiction counseling services. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Uncomfortable heart rate and body tension are common at active doses. Seek immediate medical help if any of the following occur: chest pain, seizure or convulsions, loss of consciousness, rigid or extremely elevated body temperature (hot to touch through clothing), severe confusion or complete disconnection from reality, or signs of self-harm.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Place the person on their side (recovery position) if they are unconscious or seizing — do not restrain them
- 3. Move them to a cool, quiet environment if possible
- 4. Do not induce vomiting
- 5. Monitor breathing and temperature while waiting for help
What to tell the dispatcher:
Provide the substance name (25D-NBOMe or "an NBOMe compound"), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for NBOMe overdose. Treatment is supportive.
Legal Status[edit]
25D-NBOMe occupies a complex legal position internationally. Unlike its more widely encountered analogs (25I-NBOMe, 25B-NBOMe, 25C-NBOMe), it has not been specifically named in most scheduling actions, instead falling under analog provisions, blanket bans, or structural catch-all definitions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled; Federal Analogue Act applies | 25I-, 25B-, and 25C-NBOMe placed in Schedule I on November 13, 2015.[10] 25D-NBOMe not named but covered under 21 U.S.C. § 813 if intended for human consumption. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled via N-benzylphenethylamine catch-all clause. Temporary Class Drug Order issued June 10, 2013,[11] subsequently made permanent. |
| European Union | Not specifically scheduled at EU level | 25I-NBOMe subjected to EU-wide control under Council Decision 2015/1875.[23] 25D-NBOMe not included. Member state laws vary. |
| Sweden | Controlled substance | Scheduled from August 1, 2013.[24] |
| Canada | Schedule I (CDSA) | Covered under phenethylamine blanket-ban language in the Controlled Drugs and Substances Act. |
| Australia | State-level controls | Phenethylamine blanket-ban language covers NBOMe compounds in Queensland and New South Wales from April 2014 onward.[24] |
| Brazil | Controlled | NBOMe class controlled from approximately February 2014.[24] |
Analog act considerations
In the United States, 25D-NBOMe's structural and pharmacological similarity to the Schedule I NBOMe compounds makes it subject to the Federal Analogue Act when intended for human consumption. Prosecution requires demonstrating both substantial structural similarity and substantially similar pharmacological effect — a standard that 25D-NBOMe meets by published receptor data.[1] Enforcement involves case-by-case judicial determination rather than categorical scheduling.
Frequently asked questions
What is 25D-NBOMe?
25D-NBOMe is a synthetic psychedelic phenethylamine of the NBOMe class, active at microgram doses via sublingual administration. It acts as a full 5-HT2A receptor agonist derived from 2C-D, first identified in seized drug samples in 2013.
How long does 25D-NBOMe last?
Total duration by route of administration — Sublingual: 4 – 8 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 25D-NBOMe?
Psychedex publishes a dosage table for 25D-NBOMe on this page covering these routes of administration: sublingual. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 25D-NBOMe?
The highest-severity documented interactions for 25D-NBOMe: MAOIs (Lethal), Buspirone (Dangerous), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 25D-NBOMe addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 25D-NBOMe: tolerance builds rapid; full reset takes 10 days; cross-tolerance develops with LSD, psilocybin, psilocin, mescaline, 2C-D, 2C-B, 2C-E, 2C-I, DOB, DOC, DOM, 25I-NBOMe, 25C-NBOMe, 25B-NBOMe. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, et al. (2023) Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential — Nature Communications doi:10.1038/s41467-023-44016-1
- [3] ^abcZuba D, Sekuła K (2013) Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. — Drug Testing and Analysis doi:10.1002/dta.1397
- [4] ^abcdLee JG, Hur KH, Hwang SB, Lee S, Lee SY, Jang CG (2023) Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System — ACS Chemical Neuroscience doi:10.1021/acschemneuro.3c00196
- [5] ^abcWojtas A, Gołembiowska K (2023) Molecular and Medical Aspects of Psychedelics. — International Journal of Molecular Sciences doi:10.3390/ijms25010241
- [6] ^abcdefYoon KS, Yun J, Kim YH, Shin J, Kim SJ, Seo JW, Hyun SA, Suh SK, Cha HJ (2019) 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo — Toxicology Letters doi:10.1016/j.toxlet.2019.01.004
references
- [1]
- [2] ^Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, et al. (2023) Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential — Nature Communications doi:10.1038/s41467-023-44016-1
- [3] ^abcZuba D, Sekuła K (2013) Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. — Drug Testing and Analysis doi:10.1002/dta.1397
- [4] ^abcdLee JG, Hur KH, Hwang SB, Lee S, Lee SY, Jang CG (2023) Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System — ACS Chemical Neuroscience doi:10.1021/acschemneuro.3c00196
- [5] ^abcWojtas A, Gołembiowska K (2023) Molecular and Medical Aspects of Psychedelics. — International Journal of Molecular Sciences doi:10.3390/ijms25010241
- [6] ^abcdefghYoon KS, Yun J, Kim YH, Shin J, Kim SJ, Seo JW, Hyun SA, Suh SK, Cha HJ (2019) 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo — Toxicology Letters doi:10.1016/j.toxlet.2019.01.004